Uncategorized
Dexamethasone implant associated with significantly improved visual acuity in DME patients
Patients with recalcitrant diabetic macular edema experienced significant mean gains in visual acuity after being treated with an intravitreal sustained-release dexamethasone implant, according to a study. A meta-analysis of 15 studies, including 3,859 patients, assessed the effect of Ozurdex (dexamethasone intravitreal implant 0.7 mg, Allergan) on DME. All of the studies included patients with DME who had experienced unsuccessful previous treatment with anti-VEGF therapy.